Ildong’s ‘Besivo’ shows equivalence and improved safety to Viread

“Besivo, a chronic hepatitis B treatment, is a product which proved equivalent efficacy and improved safety to Viread.”

Ildong Pharmaceutical held a press conference for ‘Besivo Tab,’ a new chronic hepatitis B treatment which recently acquired commercialization approval, with the subject ‘New Choice for Chronic Hepatitis C Treatment’ at Lotte Hotel Seoul on the 22nd.

At the conference, Profes...